{"id":675208,"date":"2023-11-03T19:34:01","date_gmt":"2023-11-03T19:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=675208"},"modified":"2023-11-03T19:34:01","modified_gmt":"2023-11-03T19:34:01","slug":"myopia-pipeline-clinical-trials-therapies-and-key-companies-vyluma-sydnexis-ocumension-limited","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myopia-pipeline-clinical-trials-therapies-and-key-companies-vyluma-sydnexis-ocumension-limited_675208.html","title":{"rendered":"Myopia Pipeline| Clinical Trials, Therapies, and Key Companies &#8211; Vyluma, Sydnexis, Ocumension limited"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Myopia Pipeline| Clinical Trials, Therapies, and Key Companies - Vyluma, Sydnexis, Ocumension limited\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Myopia Pipeline| Clinical Trials, Therapies, and Key Companies - Vyluma, Sydnexis, Ocumension limited\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s, \u201cMyopia \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n<p style=\"text-align: justify;\">DelveInsight, &ldquo;<strong>Myopia &ndash; Pipeline Insight, 2023<\/strong>,&rdquo; report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\"><strong>Download the sample page to know more @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myopia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\" target=\"_blank\"> Myopia Pipeline&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myopia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Myopia Key Highlights<\/a>&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Key Companies working in Myopia include Vyluma, Sydnexis, Ocumension limited, Santen Pharmaceutica, Cloudbreak Therapeutics, and many others.<\/li>\n<li>The Key Therapies working in Myopia include NVK002, MicroPine, and many others&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Got queries? Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myopia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Myopia Pipeline<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Myopia Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Myopia, commonly referred to as shortsightedness, is a common cause of visual disability throughout the world. The prevalence of myopia varies by country and by ethnic group, reaching as high as 70-90% in some Asian populations. Myopia occurs if the eyeball is too long or the cornea (the clear front cover of the eye) is too curved. As a result, the light entering the eye isn&#8217;t focused correctly, and distant objects look blurred. While the exact cause of myopia is unknown, there is significant evidence that many people inherit myopia, or at least the tendency to develop myopia.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;Myopia Epidemiological Segmentation&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Myopia Total Prevalent Cases<\/li>\n<li>Myopia Severity-specific Prevalence&nbsp;<\/li>\n<li>Myopia Age-specific Prevalence&nbsp;<\/li>\n<li>Myopia Diagnosed and Treated cases&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Major Players in Myopia<\/strong><\/p>\n<p style=\"text-align: justify;\">There are approx. 10+ key companies that are developing therapies for Myopia. The companies that have their Myopia drug candidates in the most advanced stage, i.e. Phase III include, Vyluma<\/p>\n<p style=\"text-align: justify;\">Phases<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s Report covers around 12+ products under different phases of clinical development like<\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Route of Administration<\/strong><\/p>\n<p style=\"text-align: justify;\">Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Intra-articular<\/li>\n<li>Intraocular<\/li>\n<li>Intrathecal<\/li>\n<li>Intravenous<\/li>\n<li>Ophthalmic<\/li>\n<li>Oral<\/li>\n<li>Parenteral<\/li>\n<li>Subcutaneous<\/li>\n<li>Topical<\/li>\n<li>Transdermal<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Molecule Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Products have been categorized under various Molecule types such as<\/p>\n<ul style=\"text-align: justify;\">\n<li>Oligonucleotide<\/li>\n<li>Peptide<\/li>\n<li>Small molecule<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Product Type<\/strong><\/p>\n<p style=\"text-align: justify;\">Drugs have been categorized under various product types like Mono Combination and Mono\/Combination.<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>&nbsp;Key Insights&nbsp;<\/li>\n<li>&nbsp;Report Introduction&nbsp;<\/li>\n<li>&nbsp;Executive Summary of Myopia&nbsp;&nbsp;<\/li>\n<li>&nbsp;Disease Background and Overview<\/li>\n<li>&nbsp;Epidemiology and patient population<\/li>\n<li>&nbsp;Myopia Emerging Therapies<\/li>\n<li>Myopia&nbsp; Market Outlook<\/li>\n<li>&nbsp;Market Access and Reimbursement of Therapies<\/li>\n<li>Appendix<\/li>\n<li>Myopia&nbsp; Report Methodology<\/li>\n<li>DelveInsight Capabilities<\/li>\n<li>&nbsp;Disclaimer<\/li>\n<li>&nbsp;About DelveInsight<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Click here to read more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myopia-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Myopia pipeline&nbsp;<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=myopia-pipeline-clinical-trials-therapies-and-key-companies-vyluma-sydnexis-ocumension-limited\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=myopia-pipeline-clinical-trials-therapies-and-key-companies-vyluma-sydnexis-ocumension-limited\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s, \u201cMyopia \u2013 Pipeline Insight, 2023,\u201d report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/myopia-pipeline-clinical-trials-therapies-and-key-companies-vyluma-sydnexis-ocumension-limited_675208.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,404],"tags":[],"class_list":["post-675208","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=675208"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/675208\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=675208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=675208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=675208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}